---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-027199"
form_type: "8-K"
ticker: null
cik: "0001733413"
company_name: "TFF Pharmaceuticals, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:16:09.483831+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TFF Pharmaceuticals FY2023 net loss $21.2M, cash $5.5M; TFF TAC positive data

## Summary
- Cash $5.5M at Dec 31, 2023; raised $1.2M gross in March 2024 offering plus warrants at $8.00.
- FY2023 net loss $21.2M (down from $31.8M in 2022); R&D $12.1M (-35%), G&A $10.6M (-23%).
- Phase 2 TFF TAC: 8/8 patients transitioned from oral Tacrolimus, no acute rejection, 4/4 continued to long-term extension.
- TFF VORI: 5/6 completed patients achieved clinical and mycologic response; no IPA-related mortality.
- Company prioritizing TFF TAC, exploring strategic alternatives for TFF VORI; new board members appointed in Q4 2023.

## SEC filing metadata
- accession: 0001213900-24-027199
- form_type: 8-K
- cik: 0001733413
- company_name: TFF Pharmaceuticals, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027199/0001213900-24-027199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027199/ea0202827-8k_tff.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-027199
- JSON: https://secwatch.observer/filing/0001213900-24-027199.json
- Plain text: https://secwatch.observer/filing/0001213900-24-027199.txt

## Key facts
- Earnings Releases
  TFF Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: net income Net loss was $21.2 million.
  - Period: the fiscal year ended December 31, 2023
  - Net income: Net loss was $21.2 million
  - Result: reported results
  source text: Net loss was $21.2 million for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1733413/000121390024027199/0001213900-24-027199-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.